FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109391465> ?p ?o ?g. }

• W2109391465 endingPage "6628" @default.
• W2109391465 startingPage "6628" @default.
• W2109391465 abstract "To evaluate the trends in the eradication rate of Helicobacter pylori (H. pylori) over the past 11 years in a single center.This retrospective study covered the period from January 2000 to December 2010. We evaluated 5746 patients diagnosed with gastric ulcers (GU), duodenal ulcers (DU), GU + DU, or nonpeptic ulcers associated with an H. pylori infection. We treated them annually with the 2 wk standard first-line triple regimen, proton pump inhibitor (PPI) + amoxicilin + clarithromycin (PAC; PPI, clarithromycin 500 mg, and amoxicillin 1 g, all twice a day). The follow-up test was performed at least 4 wk after the completion of the 2 wk standard H. pylori eradication using the PAC regimen. We also assessed the eradication rates of 1 wk second-line therapy with a quadruple standard regimen (PPI b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.) after the failure of the first-line therapy. Statistical analysis was performed with 95%CI for the differences in the annual eradication rates.A total of 5746 patients [2333 males (58.8%), 1636 females (41.2%); mean age of males vs females 51.31 ± 13.1 years vs 52.76 ± 13.6 years, P < 0.05, total mean age 51.9 ± 13.3 years (mean ± SD)] were investigated. Among these patients, 1674 patients were excluded: 35 patients refused treatment; 18 patients ceased H. pylori eradication due to side effects; 1211 patients had inappropriate indications for H. pylori eradication, having undergone stomach cancer operation or chemotherapy; and 410 patients did not undergo the follow-up. We also excluded 103 patients who wanted to stop eradication treatment after only 1 wk due to poor compliance or the side effects mentioned above. Finally, we evaluated the annual eradication success rates in a total of 3969 patients who received 2 wk first-line PAC therapy. The endoscopic and clinical findings in patients who received the 2 wk PAC were as follows: gastric ulcer in 855 (21.5%); duodenal ulcer in 878 (22.1%); gastric and duodenal ulcer in 124 (3.1%), erosive, atrophic gastritis and functional dyspepsia in 2055 (51.8%); and other findings (e.g., MALToma, patients who wanted to receive the therapy even though they had no abnormal endoscopic finding) in 57 (0.5%). The overall eradication rate of the 2 wk standard first-line triple regimen was 86.5%. The annual eradication rates from 2000 to 2010 were 86.7%, 85.4%, 86.5%, 83.3%, 89.9%, 90.5%, 88.4%, 84.5%, 89.1%, 85.8%, and 88.3%, sequentially (P = 0.06). No definite evidence of a significant change in the eradication rate was seen during the past eleven years. The eradication rates of second-line therapy were 88.9%, 82.4%, 85%, 83.9%, 77.3%, 85.7%, 84.4%, 87.3%, 83.3%, 88.9%, and 84% (P = 0.77). The overall eradication rate of 1 wk quadruple second-line therapy was 84.7%. There was no significant difference in the eradication rate according to the H. pylori associated diseases.This study showed that there was no trend change in the H. pylori eradication rate over the most recent 11 years in our institution." @default.
• W2109391465 created "2016-06-24" @default.
• W2109391465 creator A5009057362 @default.
• W2109391465 creator A5014249444 @default.
• W2109391465 creator A5018464128 @default.
• W2109391465 creator A5019618986 @default.
• W2109391465 creator A5024304363 @default.
• W2109391465 creator A5030363363 @default.
• W2109391465 creator A5041346508 @default.
• W2109391465 creator A5052193185 @default.
• W2109391465 creator A5055814473 @default.
• W2109391465 creator A5063892435 @default.
• W2109391465 creator A5064430375 @default.
• W2109391465 creator A5067938023 @default.
• W2109391465 creator A5085065184 @default.
• W2109391465 date "2012-01-01" @default.
• W2109391465 modified "2023-10-16" @default.
• W2109391465 title "Trends in the eradication rates of<i>Helicobacter pylori</i>infection for eleven years" @default.
• W2109391465 cites W1829085123 @default.
• W2109391465 cites W2013134902 @default.
• W2109391465 cites W2022948175 @default.
• W2109391465 cites W2034939896 @default.
• W2109391465 cites W2036262182 @default.
• W2109391465 cites W2037891483 @default.
• W2109391465 cites W2046352642 @default.
• W2109391465 cites W2059396942 @default.
• W2109391465 cites W2062937123 @default.
• W2109391465 cites W2068361467 @default.
• W2109391465 cites W2071687048 @default.
• W2109391465 cites W2073702415 @default.
• W2109391465 cites W2078670530 @default.
• W2109391465 cites W2093807489 @default.
• W2109391465 cites W2097678531 @default.
• W2109391465 cites W2101730203 @default.
• W2109391465 cites W2101950652 @default.
• W2109391465 cites W2123848597 @default.
• W2109391465 cites W2125173799 @default.
• W2109391465 cites W2130796878 @default.
• W2109391465 cites W2135255357 @default.
• W2109391465 cites W2136210283 @default.
• W2109391465 cites W2141650009 @default.
• W2109391465 cites W2142280478 @default.
• W2109391465 cites W2146385309 @default.
• W2109391465 cites W2152211277 @default.
• W2109391465 cites W2153165213 @default.
• W2109391465 cites W2418218623 @default.
• W2109391465 cites W93461370 @default.
• W2109391465 cites W1993037057 @default.
• W2109391465 doi "https://doi.org/10.3748/wjg.v18.i45.6628" @default.
• W2109391465 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3516214" @default.
• W2109391465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23236238" @default.
• W2109391465 hasPublicationYear "2012" @default.
• W2109391465 type Work @default.
• W2109391465 sameAs 2109391465 @default.
• W2109391465 citedByCount "28" @default.
• W2109391465 countsByYear W21093914652013 @default.
• W2109391465 countsByYear W21093914652014 @default.
• W2109391465 countsByYear W21093914652015 @default.
• W2109391465 countsByYear W21093914652016 @default.
• W2109391465 countsByYear W21093914652017 @default.
• W2109391465 countsByYear W21093914652019 @default.
• W2109391465 countsByYear W21093914652022 @default.
• W2109391465 countsByYear W21093914652023 @default.
• W2109391465 crossrefType "journal-article" @default.
• W2109391465 hasAuthorship W2109391465A5009057362 @default.
• W2109391465 hasAuthorship W2109391465A5014249444 @default.
• W2109391465 hasAuthorship W2109391465A5018464128 @default.
• W2109391465 hasAuthorship W2109391465A5019618986 @default.
• W2109391465 hasAuthorship W2109391465A5024304363 @default.
• W2109391465 hasAuthorship W2109391465A5030363363 @default.
• W2109391465 hasAuthorship W2109391465A5041346508 @default.
• W2109391465 hasAuthorship W2109391465A5052193185 @default.
• W2109391465 hasAuthorship W2109391465A5055814473 @default.
• W2109391465 hasAuthorship W2109391465A5063892435 @default.
• W2109391465 hasAuthorship W2109391465A5064430375 @default.
• W2109391465 hasAuthorship W2109391465A5067938023 @default.
• W2109391465 hasAuthorship W2109391465A5085065184 @default.
• W2109391465 hasBestOaLocation W21093914651 @default.
• W2109391465 hasConcept C126322002 @default.
• W2109391465 hasConcept C141071460 @default.
• W2109391465 hasConcept C2775981797 @default.
• W2109391465 hasConcept C2776409635 @default.
• W2109391465 hasConcept C2776962512 @default.
• W2109391465 hasConcept C2777396551 @default.
• W2109391465 hasConcept C2777498785 @default.
• W2109391465 hasConcept C2779708577 @default.
• W2109391465 hasConcept C2781025758 @default.
• W2109391465 hasConcept C2781413609 @default.
• W2109391465 hasConcept C501593827 @default.
• W2109391465 hasConcept C71924100 @default.
• W2109391465 hasConcept C86803240 @default.
• W2109391465 hasConcept C89423630 @default.
• W2109391465 hasConcept C90924648 @default.
• W2109391465 hasConceptScore W2109391465C126322002 @default.
• W2109391465 hasConceptScore W2109391465C141071460 @default.
• W2109391465 hasConceptScore W2109391465C2775981797 @default.
• W2109391465 hasConceptScore W2109391465C2776409635 @default.
• W2109391465 hasConceptScore W2109391465C2776962512 @default.

• next